Life Biosciences Appoints Industry Veteran David Guyer, M.D. to Board of Directors

Life Biosciences appointed David Guyer, M.D. to its Board of Directors effective November 1, 20251511.

David Guyer is a renowned biotechnology leader, physician–entrepreneur, and has more than 30 years of experience in drug development and commercialization1.

Dr. Guyer cofounded EyeBio (acquired by Merck in July 2024) and brought the first anti-VEGF drug for macular degeneration to market1.

He has served on over 25 company boards, taking two companies public and overseeing numerous mergers and acquisitions13.

Guyer brings scientific, operational, and governance expertise, with previous roles including Professor and Chairman at NYU School of Medicine and Venture Partner at SV Health Investors13.

Life Biosciences’ lead program, ER-100, based on its Partial Epigenetic Reprogramming (PER) platform, is slated to enter clinical trials in early 2026 to target optic neuropathies, including glaucoma and NAION15.

Bracken Darrell has stepped down from Life Biosciences’ Board of Directors concurrent with Dr. Guyer's appointment1.

Sources:

1. https://www.globenewswire.com/news-release/2025/11/03/3179183/0/en/Life-Biosciences-Appoints-Industry-Veteran-David-Guyer-M-D-to-Board-of-Directors.html

3. https://svhealthinvestors.com/people/david-guyer

5. https://www.lifebiosciences.com/life-biosciences-appoints-industry-veteran-david-guyer-m-d-to-board-of-directors/

11. https://www.globenewswire.com/en/newsroom?page=2&pageSize=10